NAOV Reddit Mentions | ChartExchange

**TL;DR:** $FEED (formerly $NAOV) has a tiny 1.1M share float, a new CEO who hasn't sold a single share, and a legacy product that just got approved for UK NHS reimbursement (recurring revenue). Most importantly, they likely cannot dilute via ATM right now due to the SEC’s "Baby Shelf" restrictions.
Here is the deep dive on why this setup is bullish at current levels.
# 1. The "Baby Shelf" Trap (Bullish for Us)
Just like we saw with other micro-caps, $FEED is currently constrained by the SEC's **"Baby Shelf Rule" (Instruction I.B.6 of Form S-3)**.
* **The Rule:** If a company’s public float is less than $75M, they can only sell (dilute) **one-third (33%)** of their public float value within a 12-month period using their S-3 shelf registration.
* **The Math:**
* **Current Float Value:** \~$1.2M - $1.5M (approx. based on \~1.1M shares).
* **The Limit:** They can only raise \~$400k-$500k total in a rolling 12-month period via the shelf.
* **The Reality:** In September 2025, they did a **$2.0M Registered Direct offering**.
* **The Conclusion:** Because that $2M raise far exceeded 33% of their current float value, they are likely **"tapped out"** on their S-3 capacity. They cannot simply flip a switch and dump ATM shares on a rally right now. To dilute, they’d likely need a full S-1 registration (which takes weeks/months) or a painful below-market deal, meaning the "easy" dilution button is disabled.
# 2. The Pivot: "GPS" for Feeding Tubes
The company changed its ticker from $NAOV to **$FEED** on Dec 12, 2025, to reflect its total pivot to the **ENvue System**.
* **The Problem:** Blindly inserting feeding tubes into patients is dangerous. If it goes into the lung instead of the stomach, it can cause pneumonia or death. Historically, hospitals use X-rays to confirm placement (slow, radiation exposure).
* **The Solution:** ENvue is an electromagnetic navigation system (think GPS) that maps the patient’s body and guides the tube in real-time.
* **Status:** FDA 510(k) cleared and effectively creates a new "Standard of Care."
* **Bonus:** On Jan 14, 2026, they launched **Reusable ENFit Syringes** (OTC), opening a new direct-to-consumer revenue stream.
# 3. The Hidden Cash Cow: UK NHS Approval
While everyone focuses on the new tech, their legacy product (**UroShield**) just hit a massive milestone.
* **News (Dec 18, 2025):** The UroShield Kit was added to the **UK NHS Drug Tariff Part IX**.
* **Why it matters:** This means the UK government (NHS) will now pay for this device. It creates a **reimbursable, recurring revenue stream** that didn't exist a few months ago. The company already received its first Purchase Order from Peak Medical (their UK distributor) immediately after this news.
# 4. Insider Alignment: The CEO is Holding
The CEO, **Dr. Doron Besser**, took over in mid-2025.
* **No Sales:** Unlike the previous management regime (which liked to sell), Dr. Besser has **zero recorded open-market sales** since taking the helm.
* **Incentives:** He was granted 180,000 RSUs in December. He is effectively "locked in" with shareholders.
# Summary
You have a stock with a **\~1.1M share float** (extremely volatile/squeeze prone), a **structural block on ATM dilution** (Baby Shelf rule), and **two validated revenue drivers** (ENvue system + UK NHS reimbursement).